
FKBP12 PROTAC dTAG-13
CAS No. 2064175-41-1
FKBP12 PROTAC dTAG-13 ( dTAG-13 )
产品货号. M13209 CAS No. 2064175-41-1
FKBP12 PROTAC dTAG-13 (dTAG-13) 是一种体内活性异双功能标签 (dTAG) 小分子,可与 FKBP12F36V 和 CRBN 结合。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
100MG | 获取报价 | 有现货 |
![]() ![]() |
200MG | 获取报价 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称FKBP12 PROTAC dTAG-13
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述FKBP12 PROTAC dTAG-13 (dTAG-13) 是一种体内活性异双功能标签 (dTAG) 小分子,可与 FKBP12F36V 和 CRBN 结合。
-
产品描述FKBP12 PROTAC dTAG-13 (dTAG-13) is an in vivo-active heterobifunctional adation tag (dTAG) small molecule that engage FKBP12F36V and CRBN, selectively degrade FKBP12F36V in a CRBN-dependent manner in cells; causes rapid degradation of nuclear and cytoplasmic FKBP12F36V fusion chimeras, and an unexpected superior antiproliferative effect of pan-BET bromodomain degradation over selective BRD4 degradation, characterize immediate effects of KRASG12V loss on proteomic signaling, and demonstrate rapid degradation in vivo.
-
体外实验TAG-13 (1-1000 nM; 4 hours; 293FTWT cells) treatment potently reduces FKBP12F36V-Nluc levels in 293FTWT cell, indicating the requirement of CRBN for the observed effects.Treatment of MV4;11 cells expressing BRD4(short)-FKBP12F36V with dTAG-13 leads to robust degradation of BRD4. dTAG-13 treatment leads to rapid degradation of BRD4 within one hou. dTAG-13 treatment leads to rapid and potent degradation of the BRD4 fusion chimera in the heterozygous and homozygous knock-in clones, with no effect on endogenous FKBP12WT. Western Blot Analysis Cell Line:293FTWT cells Concentration:1 nM, 10 nM, 100 nM, 1000 nM Incubation Time:4 hours Result:Potently reduced FKBP12F36V-Nluc levels in 293FTWT cell.
-
体内实验Following bone marrow engraftment of MV4;11 cells expressing luc-FKBP12F36V in mice, the bioluminescent signal after vehicle or dTAG-13 administration is monitored. A significant, rapid, and durable effect on bioluminescent signal is observed four hours after dTAG-13 administration, indicating effective degradation of luc-FKBP12F36V. Twenty-eight hours following the final treatment, the recovery of cellular bioluminescence to levels comparable between vehicle and dTAG-13 treatment groups is observed.
-
同义词dTAG-13
-
通路PROTACs
-
靶点PROTAC
-
受体PROTAC
-
研究领域——
-
适应症——
化学信息
-
CAS Number2064175-41-1
-
分子量1049.184
-
分子式C57H68N4O15
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO : ≥ 100 mg/mL (95.31 mM)
-
SMILESCCC(C1=CC(=C(C(=C1)OC)OC)OC)C(=O)N2CCCCC2C(=O)OC(CCC3=CC(=C(C=C3)OC)OC)C4=CC=CC=C4OCC(=O)NCCCCCCOC5=CC=CC6=C5C(=O)N(C6=O)C7CCC(=O)NC7=O
-
化学全称(1R)-3-(3,4-dimethoxyphenyl)-1-(2-(2-((6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)hexyl)amino)-2-oxoethoxy)phenyl)propyl (2S)-1-((S)-2-(3,4,5-trimethoxyphenyl)butanoyl)piperidine-2-carboxylate
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Nabet B, et al. Nat Chem Biol. 2018 May;14(5):431-441.
产品手册




关联产品
-
Fmoc-NH-PEG8-NHS est...
Fmoc-NH-PEG8-NHS 酯是一种基于 PEG 的 PROTAC 连接体,可用于 PROTAC 的合成。
-
Bromo-PEG3-C2-acid
Bromo-PEG3-C2-acid 是一种基于 PEG 的 PROTAC 连接体,可用于 PROTAC 的合成。
-
DBCO-PEG4-NHS ester
DBCO-PEG4-NHS 酯是一种基于 PEG 的 PROTAC 连接体,可用于 PROTAC 的合成。